Evidence map›Paper›PMID 31723569›Full record

ArticleOpen forum infectious diseases2019

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for

Mark H Wilcox, Oliver A Cornely, Benoit Guery, Chris Longshaw, Areti Georgopali, Andreas Karas, Gbenga Kazeem, Jose Alejandro Palacios-Fabrega, Maria J G T Vehreschild

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Management ofEClinicalMedicine · 2025
    Review
  2. Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Mark H WilcoxDepartment of Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom.ORCID 0000-0002-4565-2868
Oliver A CornelyClinical Trials Centre Cologne, ZKS Köln, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.
Benoit GueryInfectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland.
Chris LongshawAstellas Pharma Europe Ltd., Chertsey, United Kingdom.
Areti GeorgopaliAstellas Pharma Europe Ltd., Chertsey, United Kingdom.
Andreas KarasAstellas Pharma, Ltd., Chertsey, United Kingdom.
Gbenga KazeemAstellas Pharma Europe Ltd., Chertsey, United Kingdom.
Jose Alejandro Palacios-FabregaAstellas Pharma Europe Ltd., Chertsey, United Kingdom.
Maria J G T VehreschildDepartment of Internal Medicine, University Hospital of Cologne and German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.
Astellas Pharma (United Kingdom) · GBUniversity of Leeds · GBGoethe University Frankfurt · DEUniversity of Cologne · DEUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsWe aimed to assess rates of

resultsAll 356 randomized and treated patients tested positive for

conclusionsTesting for presence of copathogens in clinical trials of antibiotics could help to explain clinical failures.

Indexed as

Clostridioides difficilefidaxomicingut microbiotainfectionvancomycin

Identifiers

PMID31723569
PMCPMC6834086
OpenAlexW2986042991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.